Cargando…
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
INTRODUCTION: New medications for anaemia associated with chronic kidney disease (CKD) are desirable, owing to the limitations of erythropoiesis-stimulating agents (ESAs), the current standard of care. Molidustat is a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor that stimulates erythr...
Autores principales: | Akizawa, Tadao, Taguchi, Megumi, Matsuda, Yoshimi, Iekushi, Kazuma, Yamada, Takashi, Yamamoto, Hiroyasu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588954/ https://www.ncbi.nlm.nih.gov/pubmed/31203241 http://dx.doi.org/10.1136/bmjopen-2018-026602 |
Ejemplares similares
-
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
por: Yamamoto, Hiroyasu, et al.
Publicado: (2019) -
Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
por: Akizawa, Tadao, et al.
Publicado: (2021) -
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021) -
Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021) -
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials
por: Yamamoto, Hiroyasu, et al.
Publicado: (2023)